Home › Funds › Aequim Alternative Investments LP › ALNY

Aequim Alternative Investments LP position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

Aequim Alternative Investments LP reported holding 39,750,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$36.5M, representing 0.72% of its reported portfolio and ranking #31 among its reported holdings. Aequim Alternative Investments LP has disclosed ALNY holdings in 9 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)39.75M sh
Reported value held$36.50M
Portfolio Weight0.72%
First reportedQ3 2023
Last changeNew
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Aequim Alternative Investments LP's ALNY position evolved

Aequim Alternative Investments LP first disclosed a stake in ALNY in Q3 2023 at 30,000,000 shares (US$27.8M). The position peaked in Q3 2024 at 80,000,000 shares, worth US$93.7M. Across 9 filings, Aequim Alternative Investments LP increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 39,750,000 shares valued at US$36.5M. Notable position changes include a 35% increase in Q4 2023 (shares fell 22% over the following quarter), a 129% increase in Q2 2024 (shares rose 13% over the following quarter), a 38% trim in Q4 2024 (shares rose 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 30.00M $27.82M New
Q4 2023 40.50M $39.99M Add
Q1 2024 35.00M $33.07M Reduce
Q2 2024 80.00M $86.40M Add
Q3 2024 80.00M $93.72M Hold
Q4 2024 50.00M $53.27M Reduce
Q1 2025 40.00M $46.16M Reduce
Q2 2025 37.50M $48.81M Reduce
Q3 2026 39.75M $36.50M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has Aequim Alternative Investments LP held ALNY?

Aequim Alternative Investments LP has disclosed ALNY holdings in 9 of the last 13 reported quarters, going back to Q3 2023.

What is Aequim Alternative Investments LP's current position in ALNY?

As of Q3 2026, Aequim Alternative Investments LP holds 39.75M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $36.50M, representing 0.72% of its reported portfolio and ranking #31.

Has Aequim Alternative Investments LP been buying or selling ALNY?

In the latest 13F filing (Q3 2026), Aequim Alternative Investments LP newly opened its position in ALNY. The position peaked in Q3 2024 at 80.00M shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.